Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

Blood (2023) 142 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2023-189632

Published: 2023

Journal Articles

Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study

Salvatore Leotta, Andrea Duminuco, Antonino Mulè, Stefania Tringali, Elisa Mauro, Calogero Vetro, Cinzia Maugeri, Marina Parisi, Bruno Garibaldi, Nicola Di Renzo, Claudia Romano, Domenico Pastore, Massimo Gentile, Ernesto Vigna, Carmine Selleri, Giuseppe Milone, Uros Markovic

Blood (2022) 140 (Supplement 1): 11854–11855.

https://doi.org/10.1182/blood-2022-166546

Published: 2022

Journal Articles

T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study

Uros Markovic, Andrea Duminuco, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro, Marina Parisi, Cinzia Maugeri, Giuseppe Milone, Alessandra Romano, Francesco Di Raimondo, Salvatore Leotta

Blood (2022) 140 (Supplement 1): 11847–11848.

https://doi.org/10.1182/blood-2022-170177

Published: 2022

Journal Articles

BCL-2 and BCL-X L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study

Blood (2022) 140 (Supplement 1): 8979–8980.

https://doi.org/10.1182/blood-2022-163716

Published: 2022

Journal Articles

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Blood (2021) 138 (25): 2696–2701.

https://doi.org/10.1182/blood.2021012732

Published: 2021

Includes: Supplemental data

Journal Articles

Therapy-Related Myeloid Neoplasms (tMN) Following Treatment of Acute Myeloid Leukemia (AML): Exome Sequencing Reveals the Presence of an Ancestral Clone Refractory to Chemotherapy

Luise Hartmann, PhD, Niroshan Nadarajah, Manja Meggendorfer, PhD, Alexander Höllein, MD, Calogero Vetro, MD, Anna Stengel, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2018) 132 (Supplement 1): 1462.

https://doi.org/10.1182/blood-2018-99-112924

Published: 2018

Journal Articles

Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma

Alessandra Romano, MD PhD, Nunziatina L Parrinello, Daniele Tibullo, PhD, Calogero Vetro, MD, Cesarina Giallongo, Piera La Cava, Annalisa Chiarenza, Loredana Villari, Claudio Tripodo, MD, Giovanna Motta, Laura Caruso, Andrea Gallamini, MD, Stefano A Pileri, Francesco Di Raimondo, MD

Blood (2016) 128 (22): 1770.

https://doi.org/10.1182/blood.V128.22.1770.1770

Published: 2016

Journal Articles

In CLL with Normal Karyotype By Conventional and Genomic Array Karyotyping the Prognostic Impact of an Unmutated IGHV Status Is Stronger Than the Impact of Gene Mutations

Calogero Vetro, MD, Torsten Haferlach, MD, Manja Meggendorfer, PhD, Sabine Jeromin, PhD, Constance Regina Baer, PhD, Niroshan Nadarajah, M.Sc., Wolfgang Kern, MD, Claudia Haferlach, MD

Blood (2016) 128 (22): 4357.

https://doi.org/10.1182/blood.V128.22.4357.4357

Published: 2016

Journal Articles

Arsenic trioxide and all- trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1 -mutated AML cells

Maria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, Francesca Milano, Sara Pierangeli, Floriana Mulas, Roberta Pacini, Alessia Tabarrini, Valentina Pettirossi, Roberta Rossi, Calogero Vetro, Lorenzo Brunetti, Paolo Sportoletti, Enrico Tiacci, Francesco Di Raimondo, Brunangelo Falini

Blood (2015) 125 (22): 3455–3465.

https://doi.org/10.1182/blood-2014-11-611459

Published: 2015

Includes: Supplemental data

Journal Articles

Arginase-1 Is Increased in Hodgkin Lymphoma, Associated to Poor Outcome and Positively Correlated to Semiquantitative PET Parameters

Alessandra Romano, MD PhD, Alessandro Stefano, PhD, Cosentino Sebastiano, MD, Giorgio Russo, PhD, Nunziatina Laura Parrinello, PhD, Calogero Vetro, Piera La Cava, Daniele Tibullo, Cesarina Giallongo, Annalisa Chiarenza, Amalia Figuera, Giovanna Motta, Laura Caruso, Vanessa Mocciaro, Massimo Ippolito, MD, Ugo Consoli, MD, Francesco Di Raimondo, MD

Blood (2014) 124 (21): 4401.

https://doi.org/10.1182/blood.V124.21.4401.4401

Published: 2014

Journal Articles

Up-Regulation of Prok-2 in Granulocytes Is Present BOTH in MGUS and MM

Alessandra Romano, MD PhD, Vittorio Simeon, Piera La Cava, Nunziatina Laura Parrinello, PhD, Alessia La Fauci, Calogero Vetro, Daniele Tibullo, Cesarina Giallongo, Maide Cavalli, MD, Annalisa Chiarenza, MD PhD, Concetta Conticello, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD

Blood (2014) 124 (21): 5694.

https://doi.org/10.1182/blood.V124.21.5694.5694

Published: 2014

Journal Articles

Management of Venous Thromboembolism (VTE) in Patients with Acute Leukemia: Results from a Multicenter Study

Mariasanta Napolitano, MDPhD, Luca Valore, MD, Giorgia Saccullo, MD, Alessandra Malato, MD PhD, Calogero Vetro, Maria Enza Mitra, MD, Alessandro Lucchesi, MD, Francesco Fabbiano, MD, Donato Mannina, MD, Alessandra Casuccio, MD, Maria Ilaria Del Principe, Anna Candoni, MD, Francesco Di Raimondo, Sergio Siragusa, MD

Blood (2014) 124 (21): 3688.

https://doi.org/10.1182/blood.V124.21.3688.3688

Published: 2014

Journal Articles

Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma

Alessandra Romano, Nunziatina Parrinello, Calogero Vetro, Piera La Cava, Cesarina Giallongo, Daniele Tibullo, Giovanna Motta, Ugo Consoli, MD, Annalisa Chiarenza, MD, PhD, Giuseppe A Palumbo, Francesco Di Raimondo, MD

Blood (2013) 122 (21): 4238.

https://doi.org/10.1182/blood.V122.21.4238.4238

Published: 2013

Journal Articles

Incidence and Management Of Venous Thrombosis In Acute Leukemia: A Multicenter Study

Mariasanta Napolitano, MD, Luca Valore, MD, Giorgia Saccullo, MD, Alessandra Malato, MD, PhD, Calogero Vetro, Maria Enza Mitra, MD, Alessandro Lucchesi, MD, Francesco Fabbiano, MD, Donato Mannina, MD, Alessandra Casuccio, MD, Francesco Di Raimondo, MD, Sergio Siragusa, MD

Blood (2013) 122 (21): 3890.

https://doi.org/10.1182/blood.V122.21.3890.3890

Published: 2013

Journal Articles

Myeloid Impairment Contributes to Immunoparesis in Multiple Myeloma but Not MGUS

Alessandra Romano, MD, PhD, Nunziatina Parrinello, Calogero Vetro, Piera La Cava, Annalisa Chiarenza, MD, PhD, Concetta Conticello, MD, Giuseppe A Palumbo, Francesco Di Raimondo

Blood (2012) 120 (21): 1831.

https://doi.org/10.1182/blood.V120.21.1831.1831

Published: 2012

Journal Articles

Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,

Alessandra Romano, Vincenza Barresi, Carmela Capizzi, Cesarina Giallongo, Musso Nicolo, Piera La Cava, Calogero Vetro, Daniele Tibullo, Nunziatina Parrinello, Giuseppe A Palumbo, MD, Daniele FILIPPO Condorelli, Lance Liotta, MD, Virginia Espina, PhD, Francesco Di Raimondo, MD

Blood (2011) 118 (21): 3818.

https://doi.org/10.1182/blood.V118.21.3818.3818

Published: 2011

NARROW

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study

T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study

BCL-2 and BCL-X L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Therapy-Related Myeloid Neoplasms (tMN) Following Treatment of Acute Myeloid Leukemia (AML): Exome Sequencing Reveals the Presence of an Ancestral Clone Refractory to Chemotherapy

Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma

In CLL with Normal Karyotype By Conventional and Genomic Array Karyotyping the Prognostic Impact of an Unmutated IGHV Status Is Stronger Than the Impact of Gene Mutations

Arsenic trioxide and all- trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1 -mutated AML cells

Arginase-1 Is Increased in Hodgkin Lymphoma, Associated to Poor Outcome and Positively Correlated to Semiquantitative PET Parameters

Up-Regulation of Prok-2 in Granulocytes Is Present BOTH in MGUS and MM

Management of Venous Thromboembolism (VTE) in Patients with Acute Leukemia: Results from a Multicenter Study

Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma

Incidence and Management Of Venous Thrombosis In Acute Leukemia: A Multicenter Study

Myeloid Impairment Contributes to Immunoparesis in Multiple Myeloma but Not MGUS

Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only